People in the News
Roxi Wen has been appointed as CFO of Invitae, effective June 21. She will replace Shelly Guyer, who will focus on the company's environment, social, and governance efforts. Wen joins Invitae from Mozilla, where she has been CFO. Prior to that, she was CFO at Elo Touch Solutions, and before that, VP of finance at FleetPride. Previously, she was CFO at General Electric Critical Power. Wen holds a bachelor of economics from Xiamen University and an MBA from the University of Minnesota.
Katherine Stueland will step down as chief commercial officer of Invitae, effective June 18, to become CEO at another company.
SphingoTec has appointed Angelo Moesslang as its CFO and managing director. Prior to joining SphingoTec, he served as CEO of a US-based medical device startup and held executive roles with the Fresenius Group in Europe, Asia, and the US. Most recently, he was CFO of Fresenius Medical Care North America.
Personal Genome Diagnostics has appointed Brent Dial as its CFO. He previously served as principal at Chordata Ventures. Prior to that, he was CFO of Anheuser-Busch's High End division. He also held positions at JP Morgan Chase, Deutsche Bank Securities, and TCOM. Dial holds an MBA in corporate finance from the University of Pennsylvania’s Wharton School and is a graduate of the United States Military Academy.
Paige announced its Cofounder David Klimstra is joining the firm as its chief medical officer, effective August. He is currently chair of the pathology department at Memorial Sloan Kettering Cancer Center in New York, and he holds the James Ewing Alumni Chair in pathology. He has authored more than 450 peer-reviewed publications in the field of pathology research into pancreatic, hepatic, and gastrointestinal tumors.
Point-of-care test developer Avisa Diagnostics has appointed Barbara Bunger as its vice president of clinical development.
Bunger will be responsible for designing and executing a clinical development plan to achieve US Food and Drug Administration premarket approval for the Avisa BreathTest, a rapid, point-of-care biomarker test for the detection and monitoring of bacterial load in post-COVID-19 long haulers and for ventilator-associated pneumonia.
Prior to joining Avisa, Bunger was vice president of clinical research and regulatory strategy at Clinical Development and Regulatory Services. Previously, she was worldwide director of clinical researcher and corporate clinical development at Becton Dickinson.
Overall, Bunger has more than 30 years of industry experience in the development of clinical and regulatory strategy, global clinical research trial operations, and the planning required to generate evidence to support reimbursement and market adoption.
RNA Disease Diagnostics has appointed John Erickson as its president. Erickson will lead day-to-day operations and report to Allan Oberman, the company's cofounder and executive chairman.
Erickson joins RNA Disease Diagnostics from Erickson Healthcare Consulting, a management and strategy consulting firm he founded in 2017.
In an executive management career spanning more than three decades, he has worked with healthcare, life science, and clinical diagnostics businesses. Previously, Erickson held C-suite and senior executive leadership positions with RapidBio Systems, Johnson & Johnson, Abbott Laboratories, ITC-Nexus Dx, and Bio-Rad Laboratories.
Genomtec announced that Charudutt Shah is joining the board starting August 1. Shah is currently the marketing director at BioMérieux where he is responsible for commercial marketing in Europe, Middle East, and Africa. He oversees the launch of BioFire's syndromic infectious disease panels and instruments and develops go to market strategies for the firm's products. He previously worked at Spartan Bioscience as business development director responsible for sales, marketing, and product distribution strategies internationally. Shah was also a global marketing manager at Luminex managing the firm's PCR respiratory viral panel.
Lucira Health announced that Kevin Collins has joined the company as its chief revenue officer with global revenue responsibility. He most recently served at dialysis technology firm Outset Medical as VP of international commercial operations. He previously worked at medical robotics company Intuitive Surgical, where he served as VP of global distribution markets. He began his career at Lumenis where he was a regional sales manager for lasers.
Australian molecular diagnostics firm AusDiagnostics has appointed Marco Calzavara as its business director for the UK and Europe. He is the founder and former president of biotech firm Bioline, now part of Meridian Bioscience. The company also said that its former COO for AusDiagnostics UK, Richard Hale, will transition to a scientific consultant position for AusDiagnostics.
AltheaDx has appointed Derek Maetzold to its board. He is the founder and CEO of Castle Biosciences and previously was at Encysive Pharmaceuticals, Amylin Pharmaceuticals, Sandoz, and Schering-Plough, where he held leadership roles. San Diego-based AltheaDx develops molecular diagnostic tests for pharmacogenomics applications with a focus on mental health.